iloperidone · Vanda Pharms Inc · NDA 022192

Fanapt

Earliest generic entry, as listed · earliest of 7 marketed strengths
28 Dec 2031

Blocked by patent: US 9074254. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.

Listed patents · 11 unexpired

14 Orange Book listing rows for 11 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 9074254use U-1674 · sets the listed date28 Dec 2031
US 9074256use U-167410 Feb 2031
US 9072742use U-167416 Jan 2031
US 9074255use U-167417 Dec 2030
US 8999638use U-167428 Oct 2030
US 12606869use U-4504, U-450522 Sep 2030
US 12606869 listing rowuse U-450422 Sep 2030
US 12606869 listing rowuse U-450522 Sep 2030
US 8652776use U-168531 Aug 2030
US 10563259use U-4562, U-456324 Jul 2030
US 10563259 listing rowuse U-456224 Jul 2030
US 10563259 listing rowuse U-456324 Jul 2030
US 9157121use U-16745 Apr 2030
US 10570453use U-4562, U-456328 Mar 2028
US 10570453 listing rowuse U-456228 Mar 2028
US 10570453 listing rowuse U-456328 Mar 2028
US 8586610use U-16252 Nov 2027

Exclusivities · 1 unexpired

I-939new indication (3 years)2 Apr 2027

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 7

NDA · productFormStrengthListed expiry
022192 · 001 · RLDtablet, oral1MG28 Dec 2031
022192 · 002 · RLDtablet, oral2MG28 Dec 2031
022192 · 003 · RLDtablet, oral4MG28 Dec 2031
022192 · 004 · RLDtablet, oral6MG28 Dec 2031
022192 · 005 · RLDtablet, oral8MG28 Dec 2031
022192 · 006 · RLDtablet, oral10MG28 Dec 2031
022192 · 007 · RLDtablet, oral12MG28 Dec 2031